drugset / Trial / NCT05123365
An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a phase I/II study evaluating the optimal dose of N-acetylcysteine (N-AC) in patients with myeloproliferative neoplasms (MPN).
Timeline
- Start
- 2022-01-03
- Primary completion
- 2026-11-15
- Completion
- 2026-11-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | N-acetylcysteine | Small molecule | 600 mg | Oral |
| Subject | N-acetylcysteine | Small molecule | 1200 mg | Oral |
| Subject | N-acetylcysteine | Small molecule | 1800 mg | Oral |